Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
about
The Role of Galectin-3 in the KidneysClinical adoption of prognostic biomarkers: the case for heart failureCardiac biomarkers: new tools for heart failure managementStatins in heart failure: do we need another trial?Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapiesMacrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infectionNetwork analysis of ChIP-Seq data reveals key genes in prostate cancer.Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo StudyNovel biomarkers for cardiovascular risk prediction.Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care.Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans.Plasma levels of alpha-1-antichymotrypsin are elevated in patients with chronic heart failure, but are of limited prognostic value.Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Galectin-3 and left ventricular reverse remodelling after surgical mitral valve repair.Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.Emerging biomarkers in heart failure and cardiac cachexiaBiomarkers in cardiology--part 1--in heart failure and specific cardiomyopathiesAssessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart FailureRenal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonistsGalectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Soluble IgE receptors--elements of the IgE network.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery DiseaseGalectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D StudiesPlasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease.Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation.Plasma galectin 3 and heart failure risk in the Physicians' Health Study.Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction.Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart FailureGalectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation.Galectin 3 complements BNP in risk stratification in acute heart failure.
P2860
Q26752754-7C12B4E9-9AEF-4B64-9946-0D9868E64726Q26863716-EA3595E1-8E3B-43FE-9724-968BC2B696B2Q26991726-4B827598-0967-45C6-B00B-545AAEE098AFQ26998966-3461E5D0-C27C-425A-95F4-AE13EE9BA462Q27002436-320CE969-A355-4823-B28A-08923FE660DAQ30405402-7E5A0BA9-05FE-40E1-9B86-9432545B3BF4Q30847259-21B46701-9867-4CD4-AB0A-37305D422396Q33577541-64539190-E16B-42AA-8F45-5B1B9B0FBDD4Q33615459-F0E05DF4-D150-4F3A-9D38-7A0D9A8BE749Q33658456-0CC70FF5-BD27-43CF-B18F-15C5AFEFCC7DQ33863482-75699747-5A01-4C67-9882-B19B977F32C4Q33912126-1942363C-6A89-41C3-9731-D8EE8A5819C8Q34102031-E916265A-C3C0-4773-B1C6-8DD3C743B244Q34122713-CD95FDC6-6F0F-44DA-B055-151406E406DBQ34161212-1350B764-63FC-4780-8F20-65F96113217AQ34269132-8ABFC1A2-BAC3-4A33-91E5-EEDCB6B54DF9Q34338521-42697E84-7EAE-43F9-AAF1-4F08B18B93B5Q34528187-C6284220-2D16-4484-B544-6493575C62B6Q34836097-1D5D552A-EC74-4AA4-94CC-27E183BDFEBEQ34914470-81CD87BC-FFC5-4FD9-AFA4-51567DCF2436Q34997796-B8748C4B-8EB5-4576-8180-5C97E34B56B2Q35070734-5BBBF901-8AAE-45FF-B573-1370494865EAQ35109460-705AD6F9-5D08-4786-B554-2FF7A5558477Q35191679-A2BA25EC-3D4B-4010-B75F-1E2D56FCE9EDQ35206146-5DC945C8-BD75-43CF-ABE8-AF1CCE8F9347Q35286926-AD2E2201-7C5E-4B7D-8079-B2B79C0EAB49Q35491143-553B171E-B131-44A5-90B5-7ED49671CF79Q35562745-3F4F74F2-BFD8-4CA0-A6B9-05057B9B8691Q35680958-B0553971-1894-4258-9ABB-5FCA84DF19C5Q35689476-24104E18-A3EB-447C-8498-50E4AD43228AQ36003071-8D81D4F7-2A29-4A22-B396-7A2B27DE0C05Q36015686-347AD79C-94A6-4A0D-A7D7-5A1CA4C04CE6Q36052222-A43F82DE-4DD9-4CBA-B4D9-127FB4F725F6Q36283028-60CCA099-B15B-46A3-A7BC-A16CFAE00B9BQ36439679-DC7D526D-E10B-4E41-B3C9-0995D7FB8465Q36522700-4C9CDEAC-117E-4B79-9AD4-A8EEB61C5A7FQ36627699-44268F11-4838-4351-9DEF-69D5CFC976C2Q36757833-FC951D67-7F24-4205-BB5A-CEDC85952F77Q36877769-B1B280AA-6673-49E8-A706-874A24DB5C99Q36917873-D0328468-8820-47E8-AFB8-D2FF715E9260
P2860
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@ast
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@en
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@nl
type
label
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@ast
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@en
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@nl
prefLabel
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@ast
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@en
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@nl
P2093
P2860
P1476
Prognostic value of galectin-3 ...... : data from the DEAL-HF study.
@en
P2093
Dirk J A Lok
Erik Lipsic
Hans L Hillege
Jan Van Wijngaarden
Peter Van Der Meer
Pieta W Bruggink-André de la Porte
P2860
P2888
P304
P356
10.1007/S00392-010-0125-Y
P577
2010-02-04T00:00:00Z